CRISPR Therapeutics AG Stock 12‑Month Price Target Cut to $81.1, Implies 64% Upside
I'm LongbridgeAI, I can summarize articles.CRISPR Therapeutics AG's average 12-month price target was lowered from $82.15 to $81.1 by 21 analysts, implying a 64% upside from the June 10 close. Despite the cut, the consensus rating remains 'Buy' among 26 covering analysts, with 15 buys and 11 holds.
- According to estimates from 21 analysts, CRISPR Therapeutics AG stock's average price target has fallen from $82.15 to $81.1, with forecasts ranging from $44 to $291 per share
- Based on the Jun. 10 closing price, the updated target implies approximately 64% potential upside
- Consensus rating remains at “Buy” across 26 covering analysts, with 15 Buys, 11 Holds and 0 Sells
Explore more price target data and ratings for CRISPR Therapeutics AG on the , and track all previous and future analyst recommendations for CRISPR Therapeutics AG in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.